Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

am

During the first quarter of 2008 our clinical trial program expanded to nine clinical trials of which seven are being conducted by us and two are being sponsored by the U.S. National Cancer Institute ("NCI").

Clinical Trials - Actively Enrolling

During the first quarter of 2008, we continued to enroll patients in our Phase II combination REOLYSIN(R)/radiation and our three Phase I/II chemotherapeutic co-therapy clinical trials in the U.K. In the U.S., we continued to enroll patients in our Phase II sarcoma and in our Phase I/II recurrent malignant glioma clinical trials.

Clinical Trials - Expanded Enrollment

During the first quarter of 2008, we announced that we had met the initial criteria to proceed to full enrolment in our U.S. Phase II trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung.

According to the trial protocol, to proceed to full enrolment of 52 patients, we had to demonstrate that at least one patient in the first 38 patients treated experienced a complete or partial response, or stable disease for greater than six months. The third patient treated in the study was demonstrated to have stable disease by RECIST criteria for more than six months as measured by CT scan. A PET scan taken at the same time showed that any residual mass was metabolically inert.

This trial is a Phase II, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered intravenously to patients at a dose of 3x1010 TCID50 for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.

Eligibl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... GLEN ELLYN, Ill. , July 2, 2015 /PRNewswire-USNewswire/ ... and Colton Eakins are gaining invaluable real-world ... Institute of Technology this summer. The students ... Dr. Jeff Wereszczynski,s research group at IIT. ... Professors Dr. Tom Carter , Physics; Dr. ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate two common ... emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson ... scans and is believed to be the largest brain imaging study ever, will be ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus Pharmaceuticals, ... development of groundbreaking drugs to treat neurodegenerative diseases ... that Robert G. Miller , M.D., Director of ... Health,s California Pacific Medical Center in San Francisco, has ... for $1.5 million to help fund a Phase ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company CEO, ... PA. , The presentation took place on Tuesday, June 16 and provided ... development of APX3330 for the treatment of pancreatic cancer. A copy of the ...
Breaking Biology Technology:COD Students Participate in Prestigious Summer Internships 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... Canary Foundation, a,nonprofit organization that funds research in early ... Sam Gambhir, has,been elected as a new member of ... one of the highest honors in the fields of ... National Academy of,Sciences, serves as adviser to the nation ...
... MOUNTAIN VIEW, Calif., Oct. 21 An ... difficult to treat allures clinicians,to the approach of ... potential, stem cell therapies are believed to treat ... at a fast pace; however,both adult and embryonic ...
... Findings confirm that NanoBio,s nanoemulsion technology is effective when ... used in therapeutic applications and vaccines, ... announced,today that it will present compelling new data in ... preclinical development programs,in onychomycosis, herpes labialis, cystic fibrosis and ...
Cached Biology Technology:Canary Foundation's Dr. Sanjiv Sam Gambhir Elected to the National Academies Institute of Medicine 2Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 2Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 3NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008 2
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue guidance for ... at least 340 MSEK to that it will amount to ... growth and orders received the revenue guidance for 2015 is ... will exceed 1,500 MSEK to an updated guidance that revenue ... Due to receipt of orders of touch fingerprint sensors with ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... its patent to electronically capture, analyze and identify ... facial recognition methods. This system can: ... by an enrollment and subsequent sign-on process is ...
(Date:6/9/2015)... -- Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ) has ... & Touchless Sensing Market by Technology (Touch-based & ... (Biometric & Sanitary Equipment) & by Geography - ... offering. The total gesture recognition and ... 23.55 Billion by 2020 at a high CAGR ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... gene responsible for controlling a first key step in the ... the journal Nature tomorrow (Thursday 27 October 2005). , The ... place once a sperm enters an egg, giving it a ... animals. , The absence or mutation of this gene in ...
... to last year's groundbreaking toxicological study on water-soluble ... and Environmental Nanotechnology (CBEN) find that water-soluble carbon ... Moreover, the research finds that nanotubes, like buckyballs, ... , The findings come from the first toxicological ...
... the University of California, San Diego that appears in the ... of the species Uca crenulata may check out 100 or ... on a mate. , “As far as I know, no ... as the California fiddler crab,?said Catherine deRivera, who conducted the ...
Cached Biology News:Scientists unpick genetics of first 15 minutes of life 2Modifications render carbon nanotubes nontoxic 2Modifications render carbon nanotubes nontoxic 3Biologist Discovers What May Be World’s ‘Pickiest?Mates 2Biologist Discovers What May Be World’s ‘Pickiest?Mates 3
EnzChek cellulase substrate *blue fluorescent, 339/452...
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
... 0.5-10 Kb RNA Ladder is suitable for sizing single-stranded ... glyoxal or formaldehyde agarose gels. The ladder consists of ... 3 4 6 8 and 10 kb) to simplify ... than the other bands allowing easy orientation and identification ...
Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
Biology Products: